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The role of biomarkers is increasingly recognized in heart failure (HF) management,
for diagnosis, prognostication, and screening of high-risk patients. Beyond natriuretic
peptides and troponins, the utility of novel, emerging biomarkers is less established.
This document reﬂects the key points of a Heart Failure Association of the European
Society of Cardiology (ESC) consensus meeting on biomarker monitoring in HF.
Introduction
The role of biomarkers in heart failure (HF) is increasingly
acknowledged. These cardiac markers are used as non-
invasive way to assess the status of a patient with HF along
with the possibility of monitoring changes induced by pa-
tient management.1 Biomarkers can be used to assess to a
variety of pathophysiological processes of relevance to the
condition of a HF patient, such as fibrosis, inflammation,
myocardial injury, and remodelling.2 Specifically, monitor-
ing of biomarkers in HF can be used to make an initial diag-
nosis, to aid in prognostic stratification, and to identify a
patient’s response to therapeutic intervention.1,3
A number of HF-related biomarkers have been investi-
gated in the setting of HF (see Figure 1). However, the reli-
ability and clinical utility of most and the value of adding
biomarker evaluation to routine HF care remains unclear.
To review this area a multidisciplinary panel of the Heart
Failure Association of the European Society of Cardiology
(ESC) met to discuss the issues related to physiological
monitoring of biomarkers in HF. The key points of that con-
sensusmeeting are described in this document.
Natriuretic peptides
The human natriuretic peptide system is complex. The fol-
lowing have been described: atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), C-type natriuretic
peptide, and dendroaspis natriuretic peptide. In clinical
monitoring most attention has been directed at BNP and N-
terminal pro-BNP (NT-proBNP). These biomarkers are pep-
tide hormones synthesized by the heart but also other
organs. NP’s are the most extensively studied biomarkers
that have been used in HFmanagement. As a result of myo-
cardial stretch, the gene coding for BNP is activated and
the pro-hormone pro-BNP1–108 is produced. This is cleaved
to the biologically active BNP and the biologically inert but
stable NT-proBNP1–76.4 In addition to inducing natriuresis
NP’s are vasodilatory via vascular smoothmuscle relaxation
and they are sympatho-inhibitory. Atrial natriuretic pep-
tide is more rapidly cleared from the circulation and is now
much less used in clinical practice. However, the ANP pre-
cursor hormone mid-regional pro A-type natriuretic pep-
tide (MR-proANP) is more stable, and may be of more
clinical utility as a result.
The latest ESC guidelines5 recommended the measure-
ment of NPs to provide assistance in the diagnosis of HF in
suspected patients. Levels of NPs should bemeasured as an
initial diagnostic test, especially in the non-acute setting,
when echocardiography is not immediately available.4
Indeed, increased plasma levels may help identify patients
who need further cardiac investigation. Initial NP assess-
ment is recommended in order to rule out HF, and not to as-
certain diagnosis. Also, NPs (along with troponins, see
below) can be used to identify patients at higher risk of car-
diotoxicity and may be helpful in monitoring the use and
dosing of cardiotoxic cytotoxics.4
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Whether NPs are indicated to assist diagnosis and predict
severity and prognosis of HF,2 their utility in adjusting ther-
apies is less well-established.6–8 Studies on NP-guided
treatment in chronic HF have so far yielded promising but
inconsistent results.9–11 An individual patient meta-analy-
sis12 showed that NP-guided treatment of chronic HF re-
duced all-cause mortality in patients aged <75years and
overall reduced HF and cardiovascular hospitalization. On
the other hand, the randomized GUIDE-IT trial13 investigat-
ing the effect of NT-proBNP-guided treatment strategy on
hospitalization or cardiovascular mortality in high-risk
patients with reduced ejection fraction, found that such a
strategy was not more effective than standard treatment
approach in improving outcomes. The study was therefore
discontinued for futility.
Also, NP concentrations may be affected by cardiovascu-
lar and non-cardiovascular factors such as patient charac-
teristics, comorbidities, and HF treatments.1
Despite these limitations, NPs are cost effective, allow
repetitive and precise measurements, provide pathophysi-
ological and objective prognostic information, are useful
to assist decision-making and enhance clinical care of
HF.14,15 Integrated with the clinical assessment, serial mon-
itoring of NPs is therefore indicated as part of the routine
approach in HF management.
The increasing use of sacubitril/valsartan has meant
that NT-proBNP is preferred for BNP levels can be in-
creased after sacubitril/valsartan therapy because the
sacubitril component blocks the breakdown of circulating
BNP.
The plasma concentrations of NPs have been proven to
be useful in the initial evaluation of a patient with possible
or suspected HF. It has a particular role in assessing the
acutely dyspnoeic patient as well as the patient with insidi-
ous symptoms suggestive of HF in situation where the echo-
cardiography is not immediately available. Elevated NPs
can support a working diagnosis of HF, identifying those re-
quiring further cardiac investigation; whereas patients
with low values can be reliably considered not to have HF.
Various levels have been used. For BNP the upper limit of
normal in the non-acute setting is 35pg/mL and for NT-
proBNP it is 125pg/mL; in the acute setting, however, val-
ues are higher and more commonly used are BNP 100pg/
mL, NT-proBNP 300pg/mL, and MR-proANP 120pmol/L.
Below these thresholds ruling-out HF is reasonably reliable
and can therefore aid clinical decision-making. In inter-
preting levels in patients with established HF, such as
whether they are deteriorating or whether they are
responding beneficially to changes in therapy, the levels of
NP’s can be useful, but routinemeasurement for these pur-
poses has not been established as clinically beneficial on
major outcomes in large scale RCT’s. Other clinical fea-
tures can affect the interpretation of NP levels such as fea-
tures than elevate NP levels, such as renal impairment and
atrial fibrillation and features that reduce them such as
obesity.
Troponin in heart failure
Troponins are proteins involved in the regulation of cardiac
muscle contraction.16
Different isoforms exist within cardiac and skeletal mus-
cle. There is evidence that high-sensitive troponin (hs-tro-
ponin) is a marker of myocardial injury or necrosis in HF,
Figure 1 Potential biomarkers in the diagnosis and management of heart failure. Reproduced with permission from Nadar and Shaikh.4
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able to identify cardiotoxicity and consequently worse out-
comes and prognosis.2 In fact, measuring hs-troponin in
patients at risk of HF has been found to provide additional
predictive value.7,17 For these reasons, increased levels of
hs-troponin have prognostic value for poor outcomes in
both acute and chronic HF with reduced or preserved ejec-
tion fraction.15,18,19 In acutely decompensated patients,
the ADHERE-HF study found increased cardiac troponin to
be an independent predictor of in-hospital mortality.20
Subsequent studies have confirmed the presence of high
levels of hs-troponin in acute decompensated HF patients
to be associated to all-cause mortality.21–23 For these rea-
sons, the 2016 ESC guidelines gave a Class Ic recommenda-
tion for the use of cardiac troponins in patients with
suspected acute HF.4
Thus, hs-troponin is a promising biomarker in acute HF,
being associated to disease severity, worse clinical out-
comes, and increased mortality. Cardiac troponins are also
useful for detection of acute coronary syndromes as a pre-
cipitant of acute HF. However, elevated concentrations of
circulating cardiac troponins do not necessarily prove an
ischaemic aetiology for the majority of patients with AHF,
even without evident myocardial ischaemia. Troponins can
also aid risk stratification in acute pulmonary embolism as
a differential diagnosis of acute HF.
Routinemonitoring of troponin levels to aidmanagement
of chronic HF has not, however, been shown to improvema-
jor clinical outcomes.
Soluble suppression of tumorigenesis-2
Suppression of tumorigenesis-2 (ST2) isoforms are markers
of left ventricular hypertrophy, fibrosis and ventricular
remodelling,23 all of which are key processes in the patho-
physiology of HF.2 Soluble ST2 (sST2) is known to be a
marker of inflammation and haemodynamic stress as well
as cardiomyocyte strain. It is little affected by age, renal
function, and body mass.2 sST2 is a predictor of adverse
clinical outcomes within a HF population.24 Several studies
have shown that elevated sST2 levels are associated with
an increased risk of developing HF, greater disease severity,
and a worse prognosis.25–28
For these reasons, sST2may be potentially used for addi-
tive risk stratification beyond the NPs.29 However, caution
is needed as this marker is not HF-specific30 as other patho-
logical processes may lead to sST2 rises.23
Multimarker approach
A multimarker approach incorporates the simultaneous as-
sessment of several biomarkers with the aim of identifying
the activity of mutiple different pathophysiological path-
ways and thereby provide integrated information concern-
ing the state of the patient. There is evidence that this
combined strategy leads to improved measurement of HF
risk compared to traditional risk scores.31 The RELAX-AHF
trial showed that a multiple score composed of seven dif-
ferent biomarkers provided the more reliable prognostic
value compared any single biomarker strategy.32 Thus,
combining biomarkers may improve the ability to predict
HF outcomes.2,33–35 A multi-biomarker approach based on
NT-proBNP, hs-troponin, and ST2 was found to better iden-
tify high-risk patients for recurrent hospitalizations than
single- or double-biomarkers based scoring systems.36
A multi-biomarker approach is therefore suggested to iden-
tify high-risk patients for stratification and prevention.37,38
Conclusions
Many cardiovascular biomarkers have been studied in
HF39,40 but most do not satisfy the criteria and cannot
therefore be recommended.2,13 Beyond natriuretic pepti-
des and cardiac troponins, soluble ST2 may be indicated to
aid in the diagnosis and risk stratification/prognosis in HF2
but additional research is warranted and is in progress. In
light of the existing evidence, a multimarker approach is
suggested given the complex pathophysiological processes
underlying HF.
Conflict of interest: A.J.S.C. declares nothing related to this
work. Outside of this work, in the last 3 years, he declares having
received honoraria and/or lecture fees from: Astra Zeneca, Bayer,
Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Cardiac
Dimensions, CVRx, Enopace, Faraday, Gore, Respicardia, Stealth
Peptides, V-Wav. The other authors have no declarations to make.
References
1. Paul S, Harshaw-Ellis K. Evolving use of biomarkers in the manage-
ment of heart failure. Cardiol Rev 2019;27:153–159.
2. Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L, Acheampong E,
Zhengcan Z, Xiaoyan Q, Yunsheng X, Jingyuan M, Xiumei G, Guanwei
F. Biomarkers in heart failure: the past, current and future. Heart
Fail Rev 2019;doi: 10.1007/s10741-019-09807-z [Epub ahead of
print].
3. Squire IB. Biomarkers and prognostication in heart failure with re-
duced and preserved ejection fraction: similar but different? Eur J
Heart Fail 2017;19:1648–1650.
4. Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinical
care. Card Fail Rev J 2019;5:1–7.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ,
Falk V, Gonza´lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M,
Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano
GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/
Task Force Members; Document Reviewers. 2016 ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure: the
Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Developed
with the special contribution of the Heart Failure Association (HFA)
of the ESC. Eur J Heart Fail 2016;18:891–975.
6. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG,
Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM,
Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG,
Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B,
Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E;
European Society of Cardiology Cardiovascular Roundtable. New
strategies for the development of lipid-lowering therapies to reduce
cardiovascular risk. Eur Heart J Cardiovasc Pharmacother 2018;4:
119–127.
7. Halle´n J, Sreeharan N. Development of triglyceride-lowering drugs
to address residual cardiovascular risk: strategic and clinical consid-
erations. Eur Heart J Cardiovasc Pharmacother 2018;4:237–242.
8. Salmonson T, Dogne´ JM, Janssen H, Garcia Burgos J, Blake P. Non-vi-
tamin-K oral anticoagulants and laboratory testing: now and in the
future: views from a workshop at the European Medicines Agency
(EMA). Eur Heart J Cardiovasc Pharmacother 2017;3:42–47.
9. Agewall S. Cardiovascular pharmacotherapy and real-world data.
Eur Heart J Cardiovasc Pharmacother 2018;4:65–66.
Monitoring of biomarkers in HF M7
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/21/Supplem
ent_M
/M
5/5691323 by St G
eorge's U
niversity of London user on 23 January 2020
10. Agewall S. Cardiovascular pharmacotherapy. Eur Heart J Cardiovasc
Pharmacother 2018;4:1.
11. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC,
Ceconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar
D, Lewis BS, Agewall S. Gender differences in the effects of cardio-
vascular drugs. Eur Heart J Cardiovasc Pharmacother 2017;3:
163–182.
12. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M,
Eurlings LW, Erntell H, Persson H, O’Connor CM, Moertl D, Karlstro¨m
P, Dahlstro¨m U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto
YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treat-
ment of chronic heart failure on total mortality and hospitalization:
an individual patient meta-analysis. Eur Heart J 2014;35:1559–1567.
13. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-
Miller N, Januzzi JL, Mark DB, Pi~na IL, Passmore G, Whellan DJ, Yang
H, Cooper LS, Leifer ES, Desvigne-Nickens P, O’Connor CM. Effect of
natriuretic peptide-guided therapy on hospitalization or cardiovas-
cular mortality in high-risk patients with heart failure and reduced
ejection fraction: a randomized clinical trial. JAMA 2017;318:
713–720.
14. Januzzi JL Jr. Use of biomarkers to “guide” care in chronic heart fail-
ure: what have we learned(so far)? J Card Fail 2011;17:622–625.
15. Agewall S. Adherence to guidelines and registry data. Eur Heart J
Cardiovasc Pharmacother 2017;3:183–184.
16. Shah KS, Maisel AS, Fonarow GC. Troponin in Heart Failure. Heart
Fail Clin 2018;14:57–64.
17. Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP,
Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP,
Bo¨hm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M;
ASTRONAUT Investigators and Coordinators. Pre-discharge and early
post-discharge troponin elevation among patients hospitalized for
heart failure with reduced ejection fraction: findings from the
ASTRONAUT trial. Eur J Heart Fail 2018;20:281–291.
18. Harjola VP, Parissis J, Brunner-La Rocca HP, Celutkien _e J, Chioncel
O, Collins SP, De Backer D, Filippatos GS, Gayat E, Hill L, Lainscak M,
Lassus J, Masip J, Mebazaa A, Miro´ O`, Mortara A, Mueller C, Mullens
W, Nieminen MS, Rudiger A, Ruschitzka F, Seferovic PM, Sionis A,
Vieillard-Baron A, Weinstein JM, de Boer RA, Crespo-Leiro MG,
Piepoli M, Riley JP. Comprehensive in-hospital monitoring in acute
heart failure: applications for clinical practice and future directions
for research. A statement from the Acute Heart Failure Committee
of the Heart Failure Association (HFA) of the European Society of
Cardiology (ESC). Eur J Heart Fail 2018;20:1081–1099.
19. Hoedemaker NPG, Damman P, Ottervanger JP, Dambrink JHE,
Gosselink ATM, Kedhi E, Kolkman E, de Winter RJ, van ’t Hof AWJ.
Trends in optimal medical therapy prescription and mortality after
admission for acute coronary syndrome: a 9-year experience in a
real-world setting. Eur Heart J Cardiovasc Pharmacother 2018;4:
102–110.
20. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple
FS, Wu AH, ADHERE Investigators. Cardiac troponin and outcome in
acute heart failure. N Engl J Med 2008;358:2117–2126.
21. Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-
sensitive troponin I predict outcome in patients with decompensated
heart failure. Eur J Heart Fail 2011;13:37–42.
22. Ather S, Hira RS, Shenoy M, Fatemi O, Deswal A, Aguilar D,
Ramasubbu K, Bolos M, Chan W, Bozkurt B. Recurrent low-level tro-
ponin I elevation is a worse prognostic indicator than occasional in-
jury pattern in patients hospitalized with heart failure. Int J Cardiol
2013;166:394–398.
23. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H,
Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y. Persistently
increased serum concentrations of cardiac troponin t in patients
with idiopathic dilated cardiomyopathy are predictive of adverse
outcomes. Circulation 2001;103:369–374.
24. McCarthy CP, Januzzi JL Jr. Soluble ST2 in heart failure. Heart Fail
Clin 2018;14:41–48.
25. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL,
O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RRJ,
Lewandrowski KB, Lloyd-Jones DM, Wu AHB. Measurement of the in-
terleukin family member ST2 in patients with acute dyspnea: results
from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of
Dyspnea in the Emergency Department) study. J Am Coll Cardiol
2007;50:607–613.
26. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P,
McMurray JJ, Wikstrand J, Cleland JG, Aukrust P, Gullestad L.
Soluble ST2 is associated with adverse outcome in patients with
heart failure of ischaemic aetiology. Eur J Heart Fail 2012;14:268.
27. Binas D, Daniel H, Richter A, Ruppert V, Schlu¨ter KD, Schieffer B,
Pankuweit S. The prognostic value of sST2 and galectin-3 considering
different aetiologies in non-ischaemic heart failure. Open Heart
2018;5:e000750.
28. O’Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon
SD, Packer M, McMurray JJV, Zile MR. Independent prognostic value
of serum soluble ST2 measurements in patients with heart failure
and a reduced ejection fraction in the PARADIGM-HF trial (prospec-
tive comparison of ARNI with ACEI to determine impact on global
mortality and morbidity in heart failure). Circ Heart Fail 2018;11:
e004446.
29. Schneider D, Flores D, Mueller C. Risk stratification in acute heart
failure. Eur J Heart Fail 2018;20:945.
30. Mueller T, Jaffe AS. Soluble ST2—analytical considerations. Am J
Cardiol 2015;115(7 Suppl):8b–21b.
31. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, Goldberg
LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in
chronic heart failure. Circ Heart Fail 2012;5:183.
32. Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G,
Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, Qian M,
Teerlink JR, Metra M, Davison BA, Voors AA. A multimarker multi-
time point-based risk stratification strategy in acute heart failure:
results from the RELAX-AHF trial. Eur J Heart Fail 2017;19:
1001–1010.
33. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiol-
ogy and clinical outcomes for heart failure patients with a mid-range
ejection fraction. Eur J Heart Fail 2017;19:1597–1605.
34. Pareek A, Chandurkar N, Dharmadhikari S. Congestive heart failure:
more common as well as an important cardiovascular outcome. Eur
Heart J Cardiovasc Pharmacother 2017;3:98.
35. Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor
M, de Filippi CR, Enserro D, Blaha MJ, Cushman M, Wang TJ,
Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty
BM, Lee DS, Brouwers FP, Hillege HL, Bartz TM, Benjamin EJ, Chan
C, Allison M, Gardin JM, Januzzi JL Jr, Levy D, Herrington DM, van
Gilst WH, Bertoni AG, Larson MG, de Boer RA, Gottdiener JS, Shah
SJ, Ho JE. Predictors and outcomes of heart failure with mid-range
ejection fraction. Eur J Heart Fail 2018;20:651–659.
36. Bayes-Genis A, Nu´~nez J, Nu´~nez E, Martı´nez JB, Ferrer MP, de Antonio
M, Zamora E, Sanchis J, Rose´s JL. Multi-biomarker profiling and re-
current hospitalizations in heart failure. Front Cardiovasc Med 2016;
3:37. eCollection 2016.
37. Agostoni P, Paolillo S, Mapelli M, Gentile P, Salvioni E, Veglia F,
Bonomi A, Corra` U, Lagioia R, Limongelli G, Sinagra G, Cattadori G,
Scardovi AB, Metra M, Carubelli V, Scrutinio D, Raimondo R, Emdin
M, Piepoli M, Magrı` D, Parati G, Caravita S, Re F, Cicoira M, Mina` C,
Correale M, Frigerio M, Bussotti M, Oliva F, Battaia E, Belardinelli R,
Mezzani A, Pastormerlo L, Guazzi M, Badagliacca R, Di Lenarda A,
Passino C, Sciomer S, Zambon E, Pacileo G, Ricci R, Apostolo A,
Palermo P, Contini M, Clemenza F, Marchese G, Gargiulo P, Binno S,
Lombardi C, Passantino A, Filardi PP. Multiparametric prognostic
scores in chronic heart failure with reduced ejection fraction: a
long-term comparison. Eur J Heart Fail 2018;20:700–710.
38. Perk J. The 2016 version of the European Guidelines on
Cardiovascular Prevention. Eur Heart J Cardiovasc Pharmacother
2017;3:9–10.
39. Stenemo M, Nowak C, Byberg L, Sundstro¨m J, Giedraitis V, Lind L,
Ingelsson E, Fall T, A¨rnlo¨v J. Circulating proteins as predictors of in-
cident heart failure in the elderly. Eur J Heart Fail 2018;20:55–62.
40. Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai
AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland
T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray J.
Prognostic importance of emerging cardiac, inflammatory, and renal
biomarkers in chronic heart failure patients with reduced ejection
fraction and anaemia: RED-HF study. Eur J Heart Fail 2018;20:
268–277.
M8 I. Spoletini et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/21/Supplem
ent_M
/M
5/5691323 by St G
eorge's U
niversity of London user on 23 January 2020
